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Abstract
Background: The aim of this study was to analyze biopsychosocial factors affecting how patients cope with cancer
and adjuvant treatment and to appraise psychological distress, coping, perceived social support, quality of life and
SDM before and after adjuvant treatment in breast cancer patients compared to colon cancer patients.
Methods: NEOcoping is a national, multicenter, cross-sectional, prospective study. The sample comprised 266
patients with colon cancer and 231 with breast cancer. The instruments used were the Brief Symptom Inventory
(BSI), Mini-Mental Adjustment to Cancer (Mini-MAC), Multidimensional Scale of Perceived Social Support (MSPSS),
Shared Decision-Making Questionnaire-Patient (SDM-Q-9) and Physician’s (SDM-Q-Doc), and the European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ).
Results: Breast cancer patients reacted worse to the diagnosis of cancer with more symptoms of anxiety,
depression, and somatization, and were less satisfied with their involvement than those with colon cancer (p =
0.003). Participants with colon cancer were older and had more physical symptoms and functional limitations at the
beginning of adjuvant treatment, while there were scarcely any differences between the two groups at the end of
adjuvancy, at which time both groups suffered greater psychological and physical effects and scored lower on
coping strategies, except for anxious preoccupation.
Conclusions: Breast cancer patients need more information and involvement of the oncologist in shared decision-
making, as well as and more medical and psychological support when beginning adjuvant treatment. Both breast
and colon cancer patients may require additional psychological care at the end of adjuvancy.
Keywords: Healthcare, Patient-centered care, Breast cancer, Adjuvant therapy, Psycho-oncology
Background
Indications for adjuvant treatment for cancer are gradually
increasing and adjuvancy has a positive impact on reducing
recurrence and mortality, albeit at the expense of greater
risk of toxicity and a temporary or permanent negative im-
pact on quality of life. This should be contemplated and
included in the decision-making process for this type of
treatment.
The first visit with the medical oncologist following re-
section of non-metastatic cancer is such that it can be
difficult to explain the suitability of adjuvant treatment.
Patients come in with progressive clinical improvement
and are generally aware of their diagnosis, although it
has usually been expressed in terms of high curative pos-
sibility [1]. It falls to the oncologist to open a probabilis-
tic scenario in which both risks and benefits must be
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calculated and prognostic uncertainty, side effects, and
actual benefit for each individual patient [2] described.
Medical oncologists believe that coping style is highly
pertinent to making decisions about adjuvant treatment
or active follow-up, dealing with treatment side effects,
and the anxiety caused by prognostic uncertainty [2].
Likewise, it is commonly felt that treatment decision and
probably tolerance are influenced by physician-patient
rapport, by how information is communicated, and by
patients’ interpretation of what they are told [3]. It is
widely assumed that individuals with certain types of
cancer, such as breast cancer, cope differently than those
with other types, which affects their quality of life and
how they experience their situation [4]. Therefore, it is
apropos the validity of these assumptions be determined
and whether there are other variables that can improve
patient-physician shared decision-making (SDM). Simi-
larly, it is essential that other factors be teased out that
can contribute to better patients’ acceptance of their
situation and the possible side effects of adjuvant treat-
ment, so as not to lose out on the benefits it offers [5].
Finally, we believe that if they exist, differences in cop-
ing style among patients with different types of cancer
should be detected, so as to plan the most appropriate
support for each, as well as taking into consideration the
peculiarities of every type of cancer that can impact such
coping. Breast cancer is diagnosed when patients are still
young, around the age of 50. This makes the emotional
impact even greater at a time when they tend to be the
healthy and independent and when their family and pro-
fessional lives are of great importance [6]. Moreover, ad-
juvant treatment for breast cancer tends to be more
aggressive than for colon cancer; as such, sequelae are
potentially greater, last longer, and are more likely to
interfere with their job and social interactions. Changes
in physical appearance (hair loss, mastectomy, weight
gain due to hormone therapy), the decline of their over-
all physical condition, mainly due to adverse treatment
effects, and the uncertainty surrounding prognosis mean
that they are more likely to experience psychological dis-
tress than patients with other types of tumors such as
colon, which is typically diagnosed after the age of 60
[6]. A study by Gibbons et al. [7] and a recent meta-
analysis [8] show that coping strategies in breast cancer
mediate the relationship between illness perceptions and
adjustment to illness. Colon cancer patients have fewer
short- and long-term complaints about their quality of
life and fewer sequelae than patients with other digestive
tumors and breast cancer [9].
The aim of this study was to analyze the biopsychoso-
cial factors that affect how patients cope with cancer
and its adjuvant treatment and to appraise psychological
distress, coping, perceived social support, quality of life
and SDM before and after adjuvant treatment. Based on
the hypothesis that breast cancer patients have their
own way of coping with the disease and treatment that
does not depend on objective factors of severity, progno-
sis, or toxicity, we focus first on breast cancer patients
and then compare them to colon cancer patients.
Methods
Study design
NEOcoping is a prospective, multicenter, cross-sectional
study of the Continuous Care Group of the Spanish So-
ciety of Medical Oncology (SEOM). It was conducted
between July 2015 and July 2017 by cancer patients and
medical oncologists from 15 Medical Oncology depart-
ments in Spain. All participants signed consent forms
prior to inclusion in the study. Patients completed self-
report scales at baseline, i.e., in the week following the
first visit to the Department of Medical Oncology to de-
cide on adjuvant treatment and at the end of adjuvant
treatment. The protocol was approved by the Ethics
Committee of each hospital and the Spanish Medicines
and Health Products Agency (AEMPS). The study was
conducted in accordance with the guidelines of Strength-
ening the Reporting of Observational studies in Epidemi-
ology (STROBE) [10].
Patients
Patients ≥18 years of age with non-advanced breast and
colon cancer treated with surgery with curative intent
were eligible. In all cases, the indication for adjuvant
chemotherapy was based on international clinical guide-
lines. Patients with any serious mental illness that pre-
vented them from understanding the study and those
treated with preoperative radio- or chemotherapy, only
hormonotherapy, or adjuvant radiotherapy without
chemotherapy were excluded.
Measures
The medical oncologist who cared for each patient col-
lected and updated the data through a web-based plat-
form (www.neocoping.es). The demographic and clinical
variables recorded are listed in Table 1. The time to
diagnosis is the time elapsed from the debut of cancer
symptoms to diagnosis. The questionnaires completed
are listed in Table 2 and described below.
Mini-mental adjustment to Cancer (mini-MAC)
The Mini-MAC is a 29-item scale and assesses cancer-
specific coping strategies as adaptive (cognitive avoidance,
fighting spirit, and fatalism) or maladaptive (helplessness
and anxious preoccupation) [11, 12]. Each item is rated on
a 4-point Likert scale ranging from 1 (definitely does not
apply to me) to 4 (definitely apply to me). Raw score is
transformed into a percentage with 0 indicating the lowest
possible level of cancer-specific coping strategies and 100
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indicating the highest. Cronbach’s alpha coefficients for
each domain ranged from 0.62–0.88 [12, 13].
Brief symptom inventory (BSI)
The BSI-18 consists of 18-item divided into three di-
mensions (somatizations, depression, and anxiety), as
well as a total score, the Global Severity Index (GSI),
which summarizes the respondent’s overall emotional
adjustment or psychological distress over the last 7 days
[14]. Raw scores are converted to T-scores based on
gender-specific normative data [14], higher scores indi-
cating greater psychological distress. Each item is rated
on a 5-point Likert scale. Cronbach’s alpha varied from
0.81 to 0.90 [14].
Shared Decision-Making Questionnaire-Patient (SDM-Q-9)
and Physician’s (SDM-Q-doc) versions
The SDM-Q-9 and SDM-Q-Doc are short and accurate
questionnaires that evaluate the SDM process from the
patient’s [15] and physician’s perspective [16]. Each
questionnaire contains 9-item, each describing one step
of the SDM process [17]. Items are scored from 0 to 5
on a 6-point Likert scale. A total raw score between 0
and 45 is possible. Raw score is transformed into a per-
centage with 0 indicating the lowest possible level of
SDM and 100 indicating the highest. Test-retest reliabil-
ity was between 0.88 and 0.90 [18, 19].
Multidimensional Scale of Perceived Social Support (MSPSS)
The MSPSS evaluates social support and includes 12-
item related to three sources of social support: family,
friends, and significant other [20]. Responses are pro-
vided that range from 1 (very strongly disagree) to 7
(very strongly agree), scores on scale range from 12 to
84 with higher scores indicating greater perceived social
support. The MSPSS is extensively used in both clinical
and non-clinical samples and has been found to be reli-
able and valid [21].
European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire (EORTC-QLQ-
C30)
EORTC QLQ-C30 is commonly employed in Europe
and its validity has been well established [5, 22]. The 30-
item comprise four subscales, ‘Functioning, ‘Symptom,
‘Health Status‘, and ‘General Quality of Life’ and are
scored from 1 to 4. Scores for each dimension range
from 0 to 100 (0, minimum quality of life; 100, max-
imum). Higher functional scale, global health status and
general quality of life scores and lower symptoms scale
scores indicate better QoL.
Statistical analyses
Demographic data and survey responses were analyzed
with descriptive statistics using absolute frequencies for
categorical data, mean and standard deviation (SD) for
Table 1 Sociodemographic and clinical characteristics of the entire sample and of the patients with colon and breast cancer who
went to the Medical Oncology department to decide on adjuvant treatment after curative resection of the cancer
Demographic and clinical characteristics TOTAL (n = 497) Colon cancer (n = 266) Breast cancer (n = 231) t/χ2 p
Gender: n (%)
Women 337 (67.8) 111 (58) 231 (100) 178.288 0.001
Men 160 (34.5) 155 (42) 0
Age (years): mean (SD) 58.4 (12.1) 63.1 (11.1) 52.9 (11.0) 9.791 0.001
Marital Status:
Married/ partnered: n (%) 342 (68.8) 194 (72.9) 148 (72.9) 2.970 0.085
Educational level: n (%)
Basic 362 (72.8) 206 (84.7) 156 (76.8) 4.546 0.033
Intermediate 135 (27.2) 60 (15.3) 75 (23.2)
Unemployed: n (%) 281 (56.5) 163 (61.2) 88 (38.0) 10.462 0.001
Tumor stage: n (%)
I-II 297 (59.8) 89 (33.5) 208 (90.1) 204.075 0.001
III 200 (40.2) 177 (66.5) 23 (9.9)
Time to diagnosis (days): mean (SD) 176 (99) 192 (107) 156 (83) 2.213 0.027
Type of adjuvant treatment
Chemotherapy 331 (66.6) 255 (95.8) 76 (32.9) 220.344 0.001
Chemotherapy and radiotherapy 166 (33.4) 11 (4.2) 155 (67.1)
Risk of relapse (%): mean (SD) 37.6 (37.6) 43.8 (21.1) 30.4 (15.8) 7.859 0.001
Abbreviations: n number, SD standard deviation
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quantitative data and obtaining information from the en-
tire sample and grouped by type of cancer. Bivariate chi-
square and t tests were used to assess differences between
colon and breast cancer in terms of socio-demographic,
clinical and psychological characteristics (impact of can-
cer, coping strategies, social support, quality of life and
SDM). Analysis of the variance of repeated measures was
performed on the basis of scores obtained before starting
and after finishing adjuvant treatment (impact of cancer,
coping strategies and quality of life). These analyses were
age-adjusted. Cohen’s effect size (d) and eta squared (η2)
were used to assess the degree to which differences in
continuous variables were associated with group status
(breast or colon cancer). Cohen’s d was reported as an in-
dicator of effect size of the differences, with d > 0.2 repre-
senting a small, d > 0.5 a medium and d > 0.8 a large effect
size [23] and eta-squared ranges between 0 and 1, with η2
~ 01 for a small, η2 ~ .06 for a medium and η2 > .14 for a
large effect size [24]. The data were analyzed using SPSS
version 23.0 (IBM Corp., Armonk, NY, USA).
Results
We screened 572 patients; 497 were eligible for this ana-
lysis and 75 were excluded as shown in the flow dia-
gram, Fig. 1. Socio-demographic and baseline clinical
characteristics are presented in Table 1. Two hundred
and sixty-six (266) patients had colon cancer [75% stage
III and 25% stage II with some factor associated with
risk of recurrence] and 231 had breast cancer [stage I-III
with criteria indicating adjuvant chemotherapy]. The
type of surgery for breast cancer was mastectomy in 42
patients (18%) and lumpectomy in the remaining 82%.
The mean age of patients with colon and breast cancer
was 63.1 and 52.9 years, respectively. Breast cancer pa-
tients had a higher educational level than those with
colon cancer. Although the proportion of patients who
did not work was high in both groups, it was higher
among patients with colorectal cancer mainly because,
since they were older, more of them were retired,
whereas among the breast cancer subjects, 38% were un-
employed. Patients with colon cancer were diagnosed
Table 2 Differences in the impact of cancer, coping strategies, social support, quality of life, and shared decision making by type of
cancer,— colon or breast — in patients who went to the Medical Oncology department to consider adjuvant treatment
TOTAL (n = 497) Colon cancer (n = 266) Breast cancer (n = 231) t p
Psychological distress (BSI-18)a 63.5 (6.8) 62.4 (6.5) 64.9 (6.9) −3.903 0.001
Anxiety 61.9 (7.7) 60.8 (7.4) 63.2 (5.7) −3.218 0.001
Depression 60.4 (5.9) 59.5 (5.7) 61.4 (6.1) −3.400 0.011
Somatization 60.8 (6.7) 59.9 (6.3) 61.8 (6.9) −2.978 0.003
Coping with cancer (M-MAC)b
Adaptive 65.7 (17.3) 65.7 (17.3) 66.6 (14.7) −0.595 0.552
Fighting spirit 78.8 (17.7) 78.5 (17.6) 79.1 (17.7) −0.385 0.701
Cognitive Avoidance 52.3 (25.9) 51.6 (26.3) 53.1 (25.3) −0.625 0.532
Fatalism 67.2 (18.9) 66.9 (20.1) 67.5 (17.5) −0.311 0.756
Maladaptive 32.6 (39.4) 30.2 (19.2) 30.10 (18.8) 0.108 0.914
Helplessness 18.2 (18.2) 19.3 (18.6) 16.7 (17.7) 1.479 0.140
Anxious preoccupation 42.1 (25.5) 41.1 (25.4) 43.3 (25.7) −0.893 0.372
Social support (MPSS)c
Family 25.7 (3.5) 26.2 (2.9) 25.2 (4.1) 3.089 0.002
Friends 23.6 (4.8) 22.9 (5.1) 24.8 (4.3) −3.672 0.001
Significant other 25.6 (3.8) 25.8 (3.7) 25.4 (3.9) 1.106 0.269
Quality of life (EORTC QLQ-C30)b
Functional scale 82.6 (11.3) 83.6 (11.1) 81.3 (11.4) −2.183 0.030
Symptom scale 82.7 (11.7) 84.1 (10.5) 80.9 (12.8) −2.829 0.005
Health status Scale 56.8 (19.7) 56.6 (19.3) 57.1 (20.3) −0.155 0.877
General quality of life scale 74.4 (12.4) 74.3 (12.2) 74.1 (12.7) 0.466 0.642
Shared Decision Making (SDM)b
Physician (SDM-Q-Doc) 91.3 (9.1) 91.8 (8.5) 90.7 (90.8) 1.296 0.196
Patient (SDM-Q-9) 82.2 (19.3) 84.5 (17.8) 77.8 (20.7) 2.938 0.003
Abbreviations: BSI Brief Symptom Inventory, EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, M-MAC
Mini-Mental Adjustment to Cancer, MSPSS Multidimensional Scale of Perceived Social Support, SDM Shared Decision Making
a T score. b Scale from 0 to 100. c Scale from 4 to 28 for each source of support
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later, had more advanced disease with increased risk of
relapse, and treatment tended to consist of surgery and
adjuvant chemotherapy, while the most common treat-
ment for breast cancer patients was surgery, chemother-
apy, and radiotherapy.
Psychological adaptation to cancer
Differences in psychological adaptation by cancer type
are reported in Table 2.
Cancer diagnosis
The impact of the cancer diagnosis was less negative
among colon cancer patients, these patients presented less
psychological distress than breast cancer patients (t(441) =
− 3.903, p < 0.001, Cohen’s d = 0.372). Breast cancer pa-
tients experienced the diagnosis more negatively, with
more symptoms of anxiety, depression, and somatization
than colorectal cancer patients based on the BSI-18 score.
At the beginning of treatment, there were no differences
between groups in terms of quality of life, although more
physical symptoms (p = 0.005, Cohen’s d = 0.204) and
functional limitations (p = 0.030, Cohen’s d = 0.042) were
reported among colon cancer sufferers.
Coping with cancer
Individuals with colon and breast cancer used adaptive
strategies. Of the five coping patterns identified, most used
fighting spirit and fatalism, while hopelessness was the
least common. Though coping patterns were similar, each
group looked for social support from different sources. Pa-
tients with breast cancer sought more support among
friends (p < 0.001, Cohen’s d = 0.402), whereas participants
with colon cancer turned more to relatives for support
(p < 0.001, Cohen’s d = 0.281).
Fig. 1 Flow Diagram of the NEOcoping study
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Shared decision-making
Oncologists were very satisfied with SDM and felt that
they informed their patients appropriately without signifi-
cant differences between oncologists who treat breast or
colon cancer. However, participants with breast cancer
were less satisfied than those with colon cancer (p = 0.003,
Cohen’s d = 0.347), probably because they wanted to par-
ticipate more actively in SDM.
Psychological change after adjuvant treatment
We report data on 114 patients with colon cancer and
89 with breast cancer; i.e., those who had completed ad-
juvant treatment at the time of this analysis (Fig. 1).
To examine the change in psychological parameters
resulting from the effect of chemotherapy, the BSI-18,
Mini-MAC, and EORTC-QLQ-C30 scales were com-
pleted before and after adjuvant treatment and a variance
analysis of repeated measures was performed considering
pre- and post-adjuvancy scores (see Table 3 and Fig. 2).
Both breast and colon cancer patients reported more
somatic symptoms (p = 0.001, η2 = 0.285), and greater
psychological distress after completing treatment (p =
0.001, η2 = 0.057), with no differences on the basis of the
primary tumor.
In terms of post-adjuvancy coping strategies, both
groups displayed fewer adaptive (F(1,196) = 11.602, p =
0.001, η2 = 0.056) and maladaptive strategies (p = 0.003,
η2 = 0.045). Insofar as adaptive strategies are concerned,
both groups decreased fighting spirit (p = 0.001, η2 =
0.066) and fatalism (p = 0.001, η2 = 0.065), while cogni-
tive avoidance remained stable. As regards maladaptive
strategies, both groups exhibited less hopelessness (p =
0.007, η2 = 0.037) and anxiety (p = 0.009, η2 = 0.034). No
differences were found according to tumor type.
In relation to the quality of life, most patients stated
that they suffered a significant decrease in their quality
of life after adjuvant treatment on the functioning scale
(p = 0.001, η2 = 0.200), health status scale (p = 0.006, η2 =
0.039), and on the general quality-of-life scale (p = 0.001,
η2 = 0.083). No differences were found by tumor type.
Discussion
NEOcoping is a prospective, multicenter study of the
Continuous Care Group of the Spanish Society of Med-
ical Oncology (SEOM) that brings together 15 Medical
Oncology departments in Spanish hospitals and 497 eva-
luable patients. To the best of our knowledge, this is
among the largest series of variables covering different
aspects of the process of coping and SDM on the
Table 3 Multivariate analysis of repeated measures before and after adjuvant treatment in patients with colon and breast cancer
and curative surgery for the cancer
Scales Colon cancer (n = 114) Breast cancer (n = 89) ANOVA results, F
Pre Mean (SD) Post Mean (SD) Pre Mean (SD) Post Mean (SD) Time x tumor Time Tumor site
Psy. distress (BSI) a 62.3 (6.4) 64.6 (6.7) 64.4 (7.4) 65.9 (6.8) 0.295 11.223** 4.691
Anxiety 60.3 (7.1) 60.0 (7.2) 62.1 (8.3) 61.1 (7.6) 1.662 0.414 2.426
Depression 59.4 (5.5) 60.1 (5.7) 60.5 (6.2) 60.2 (5.7) 1.246 0.248 0.845
Somatization 59.9 (6.1) 64.4 (7.2) 61.3 (6.7) 65.9 (7.1) 0.034 80.033** 3.112
Coping with cancer (M-MAC) b
Adaptive 64.8 (18.1) 63.2 (19.5) 66.3 (14.2) 59.6 (17.8) 4.199 11.602** 0.205
Fighting spirit 77.2 (18.2) 72.4 (20.9) 77.7 (16.9) 71.8 (21.2) 0.160 13.826** 0.002
Cognitive Avoidance 51.4 (26.6) 52.3 (28.1) 53.1 (25.2) 48.7 (25.3) 2.056 0.916 0.084
Fatalism 35.8 (20.6) 63.7 (22.3) 38.7 (17.9) 58.7 (22.1) 6.039 13.707** 0.165
Maladaptive 29.3 (18.5) 23.2 (18.2) 29.1 (19.3) 27.2 (20.3) 2.606 9.179** 0.612
Helplessness 20.1 (19.1) 13.7 (17.5) 16.1 (17.6) 14.3 (19.5) 2.402 7.509** 0.610
Anxious preoccupation 38.3 (22.9) 32.5 (22.5) 42.0 (26.0) 39.6 (24.7) 1.203 6.904** 3.124
Quality of life (EORTC-QLQ-C30) b
Functional scale 83.5 (11.4) 77.9 (13.7) 82.5 (10.4) 75.5 (14.3) 0.572 49.525** 1.046
Symptom scale 83.3 (10.3) 84.1 (13.4) 83.1 (13.4) 82.4 (11.7) 0.758 0.008 0.412
Health Status scale 59.8 (18.1) 56.4 (19.4) 62.8 (17.1) 57.0 (20.3) 0.494 7.065** 0.710
Quality of life scale 75.3 (11.1) 72.6 (12.1) 76.6 (10.6) 71.3 (12.6) 1.238 16.877** 0.021
These analyses were age-adjusted.
Abbreviations: BSI Brief Symptom Inventory, EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, M-MAC
Mini-Mental Adjustment to Cancer, Pre before adjuvant treatment, Post after adjuvant treatment, Psy psychological, SD Standard Deviation
*p < 0.01 (two-tailed), ** p < 0.001 (two-tailed)
a T score. b Scale from 0 to 100
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suitability of adjuvant treatment. The study is ongoing,
and results will be completed over time.
This study examines breast and colon cancer because
they are common tumors, proven to benefit from adju-
vant treatment, and with relatively high cure rates. Bea-
ver et al. compared the same cancers and analyzed
preferences in decision-making [25]. They found a more
active and demanding attitude in breast cancer patients,
which coincides with our findings in this regard. Our
study, however, investigates a greater number of clinical,
psychological, quality of life, and SDM variables over
two very different periods of time: first, following cura-
tive surgery and prior to initiating adjuvant treatment
and second, at the end of treatment.
Our results suggest that breast cancer patients respond
worse to their cancer diagnosis, and are less satisfied with
Fig. 2 BSI-18, Mini-MAC and EORT-QLQ-C30 scales before and after adjuvant treatment applied to 203 of the patients
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their doctors than colon cancer patients. The latter partic-
ipants were older and had more physical symptoms and
functional limitations at the beginning of adjuvant treat-
ment. Previous studies evaluating patient preferences re-
vealed that breast cancer patients are younger, healthier,
and have more active or cooperative roles [5, 26] while in-
dividuals with colon cancer would like to be informed and
involved in decision-making, but do not necessarily want
to make autonomous treatment choices and many prefer
a more passive role [27]. In addition, the greater psycho-
logical impact of breast cancer, with more symptoms of
anxiety, depression, and somatization is not only explained
by the fact that it affects younger patients, at a time of
maximum professional and family activity, but also by sig-
nificant changes in appearance (hair loss, mastectomy,
weight gain due to hormonotherapy), physical symptoms,
and uncertainty about prognosis [6, 7].
Another difference between the two groups is social
support. Breast cancer patients look for support from
friends and colleagues, while subjects with colon cancer
are more family-dependent. This may be a simple gener-
ational issue related to the younger age of breast cancer
patients.
At the end of adjuvant treatment, there are fewer
differences between the groups that are most affected
both psychologically (with more somatic symptoms and
greater psychological distress) and physically (with lower
functional and quality-of-life scores). Likewise, both
groups score low on coping strategies except for anxious
preoccupation in response to what they may perceive as
a kind of a sword of Damocles.
Based on these results, it can be hypothesized that
patients are better prepared to fight at the start of treat-
ment and are at their worst psychologically once adju-
vant treatment has ended. The subsequent scenario is
no longer one of fighting, but of repairing damages and
returning to their previous activities and roles, for which
they do not yet feel ready. This last observation is espe-
cially relevant, given that from that point forward, most
patients (at least according to the most usual follow-up
protocols) will be left without medical supervision for
months after a long series of frequent medical visits dur-
ing adjuvant treatment. Perhaps, on the basis of these
results, we should consider psychological intervention
precisely at this point in time. A similar methodology
was used by Boinon et al., who interviewed 102 women
with breast cancer after surgery and at the end of adju-
vant treatment, with special attention paid to the influ-
ence of social support on perceived well-being [27].
Patients responded to self-report questionnaires asses-
sing psychological adjustment (depressive symptoms and
anxiety related to cancer), social participation concern-
ing their illness, and perceived social support (generic
and cancer-specific).
Study limitations
This study is not without its limitations that must be
taken into consideration. First of all, the use of self-
report, subjective measures cannot accurately reflect pa-
tients’ experiences, expectations, and behaviors, as they
are limited by response bias (social desirability, inaccur-
ate memory, etc.), which we have attempted to minimize
by reminding patients that answers were completely an-
onymous and that there were no right or wrong answers.
Second, we have compared patients with breast and
colon cancer, and 100% in stage I-III; therefore, the re-
sults may not generalize to patients with other tumors
or in stage IV disease. Another limitation, despite sex
was taken into consideration in subgroup analyses, is
that breast cancer patients were mostly women, while
colon cancer patients were men and women. Therefore,
characteristics due to sex may have influenced the
results. Finally, there are numerous factors that can in-
fluence treatment decision and that have not been con-
sidered, such as the presence of comorbidities, type of
treatment, and side effects.
Given the size of our sample and the prospective na-
ture of the evaluation, we consider the outcomes to be
reliable, robust, and relevant, which allows us to suggest
measures to improve coping and psychological well-
being at the beginning and end of adjuvant chemother-
apy. We believe this study to be a benchmark in this
field. The limitation of exploring only two-time periods
in a continuous process can be overcome with subse-
quent surveys, such as in the study by Ganz et al. [28]
who collected data from 558 women with breast cancer
after surgery and at 2.6 and 12 months, revealing signifi-
cant physical and psychosocial recovery in the first year
after treatment had been completed.
Conclusions
In conclusion, NEOcoping helps us to comprehend how
patients with non-metastatic colon and breast cancer
cope with cancer before and after adjuvant treatment.
Moreover, we have identified aspects that impact quality
of life and psychological well-being. The results point to-
ward breast cancer patients needing more information
and involvement of the oncologist in SDM and more
medical and psychological support initially. Patients with
colon and breast cancer suffered greater psychological
and physical effects and scored lower on coping strat-
egies, except for anxious preoccupation, after completing
treatment. This indicates that we should modify the tim-
ing of psychological care for both groups, increasing
support at times when, at present, patients are typically
left alone; i.e., after the end of adjuvant treatment.
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